about
Chemoprevention of Breast Cancer by Dietary PolyphenolsEvolving concepts in cancer therapy through targeting sphingolipid metabolismEngineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic DeliveryBerberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expressionBioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicitySynthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cellsStrategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells.Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.Calorie restriction combined with resveratrol induces autophagy and protects 26-month-old rat hearts from doxorubicin-induced toxicitySelenorhodamine photosensitizers for photodynamic therapy of P-glycoprotein-expressing cancer cellsFocal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat.Mutation in integrin-linked kinase (ILK(R211A)) and heat-shock protein 70 comprise a broadly cardioprotective complex.Shengmai injection improved doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer.Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment.Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced DamageStrategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complexInhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1.The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cellsComparison of adipose tissue- and bone marrow- derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats.Doxorubicin-induced cardiomyopathy 17 years after chemotherapyDeletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in miceA Young Man with a Mediastinal Mass and Sudden Cardiac ArrestRemission of chronic anthracycline-induced heart failure with support from a continuous-flow left ventricular assist deviceA composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.Tert-butylhydroquinone ameliorates doxorubicin-induced cardiotoxicity by activating Nrf2 and inducing the expression of its target genes.Fluorescence properties of doxorubicin in PBS buffer and PVA films.Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases.Rapidly Progressing Chagas Cardiomyopathy.Cardiotoxicity of anthracycline therapy: current perspectivesModeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesDoxorubicin induced heart failure: Phenotype and molecular mechanisms.Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.
P2860
Q26773449-DCB6DC97-6A6C-408D-AB56-8A62DEF5897DQ26863646-F78CA8C6-A214-4492-8E07-9709A985CCEFQ28087367-AA2D97D9-5417-49DB-8FD8-DD462F6625EFQ28484395-A6C09E41-C812-4098-B0EC-52EA7E9E649FQ28488006-0F0A8E77-BC40-42DA-B924-D3B51922D163Q33706296-BD5AA0CA-E184-4A30-A2C5-F92EFEC324CFQ33757127-D0C9D001-EE1B-44F9-A3EF-AB208C7DE0C2Q33824440-56211DBE-A1B9-4732-AE85-81C280576D43Q33829335-E9893235-F178-4110-AC7D-A8FAAE3D4D61Q33853732-359122B1-6FEA-46FD-A67F-3EC67CC548E9Q34098331-75DE3D75-3A15-492C-9E2E-EED8B67275E1Q34394090-42295222-9635-41AD-A666-B5DF0972EA02Q34541922-BEFE8C14-AAA8-47B8-B090-EE69959E5E40Q34760735-899989D5-ABA8-43B9-B319-CB694109DF3DQ35048027-65321233-30CA-40AD-9EB3-610743549D4AQ35206783-B93829A2-6824-42C0-B130-2B80AD188CC6Q35222202-D20A7CF1-0FED-482A-8A75-E0E1D4BDC052Q35317195-077D8950-3E45-45CA-930E-56AAB7E4E4DFQ35359370-C8CD6023-4490-4076-A416-0BF04226471AQ35566390-0799874F-7CC7-478A-BB51-95D40CEFF264Q35604952-0C43778B-1F33-48E6-A405-DC74B42B26BFQ35681478-804B7593-D653-4EC6-A161-5DD255FD08F4Q35824678-09956989-7E7D-462F-8BA8-79FE7083FC92Q35868154-FF593C7B-D17F-42E2-8138-35AE0F030AB8Q35986990-6A792B35-2F23-4F35-B334-4EFF981E1EF9Q35987027-B3EB37CB-C4D8-4997-8C9B-13CFF48299E4Q36011893-D8A6EDFD-F8A3-4720-85D2-4B5B2F735E14Q36022217-26972497-64F3-4D63-8D44-C3126577149AQ36030052-8A8466EB-C40E-44C3-BA90-A0AA0B4F0FD8Q36050604-7A7C69C8-DFF1-4024-9EBF-30CBDFA3D119Q36176616-6FC58375-58E2-4FE5-9A61-79534DED09FCQ36234061-C4A1E17D-3973-4FEF-9E5B-8D5504FF9E9CQ36309459-A165271B-E9CA-4809-A89E-8B06F20C3B67Q36340797-C87CBB5B-16FF-45C6-9BB4-42B89B06AD66Q36670771-0E61A828-61F7-4B52-903A-A0F32D83F6B1Q36776143-B732896D-24D6-45F8-9E24-4928B6893260Q36845348-75FD5BDA-2810-4E5B-AF8B-48BE3B2D6136Q36864827-8B84D556-16FE-4663-A16C-08525A07D9D1Q36912561-AB820C5F-A8EE-45E5-8AF7-9FAE87C8EBAEQ37042612-B23F688B-8C36-4918-ACDB-538E524855F8
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Doxorubicin cardiomyopathy
@ast
Doxorubicin cardiomyopathy
@en
Doxorubicin cardiomyopathy
@nl
type
label
Doxorubicin cardiomyopathy
@ast
Doxorubicin cardiomyopathy
@en
Doxorubicin cardiomyopathy
@nl
prefLabel
Doxorubicin cardiomyopathy
@ast
Doxorubicin cardiomyopathy
@en
Doxorubicin cardiomyopathy
@nl
P2093
P2860
P3181
P356
P1433
P1476
Doxorubicin cardiomyopathy
@en
P2093
Jianqing Zhang
Joel S Karliner
Kanu Chatterjee
Norman Honbo
P2860
P304
P3181
P356
10.1159/000265166
P407
P577
2010-01-01T00:00:00Z